Home > Novartis AG acquires Rights to Synacthen
Transaction · Life Science

Novartis AG acquires Rights to Synacthen

Novartis AG acquired Rights to Synacthen, a life science company in United States.

Deal at a glance

TargetRights to Synacthen Buyer Novartis AG SectorLife Science LocationUnited States ValueNot disclosed

Target company

Rights to Synacthen
United States
Life Sciencesector
-founded
Activestatus
View the company profile →

Buyer

Company · 35 deals on record
35deals, all time
16in this sector
2021latest

Members only

Contact details at the buyers and sellers
The full deal history of every party
Co-investors and the other advisors on this deal
Deal value and revenue or EBITDA multiples

Related deals

Ollin Biosciences, Inc.Same sector and country · Nov 2026
OmnioseSame sector and country · Nov 2026
Orbus Therapeutics, Inc.Same sector and country · Oct 2026

Questions about this deal

Who acquired Rights to Synacthen?Novartis AG acquired Rights to Synacthen.

What type of deal was it?It was a transaction in the life science sector.

See the full picture on AcquityDataContacts, full deal histories, co-investors and deal values. Free for a day with your Google account, no card needed.
Try it free
Data updated daily on AcquityData (Acquity Data).